Consistent with the in vitro assay, the CAR‐T treatments against GPC3+ xenografts constructed using HepG2 and Hep3B cells, via either p.v. or t.v. injections, demonstrated robust anti‐tumour efficacy (Figure 2B,C; Figure S3). Here, GPC3 is linked to neoplasm.